(Total Views: 485)
Posted On: 11/16/2023 3:53:52 PM
Post# of 154604
I saw the following report by Dr. Mazen Noureddin (who is on our Scientific Advisory Board) at the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases.
I look forward to the day when our advisors report on Leronlimab.
Ohm, is this a serious threat to Leronlimab's MASH potential? Excerpts and link are inserted below.
BOSTON -- Treatment with an investigational thyroid hormone receptor-beta (THR-β) agonist significantly reduced liver fat content in patients with metabolic dysfunction-associated steatohepatitis (MASH), a placebo-controlled phase IIa trial showed.
Significant reductions from baseline were seen as early as 6 weeks with the novel oral compound (TERN-501). By 12 weeks, mean relative reductions ranged from 27% to 45% with 3-mg and 6-mg doses of the THR-β agonist, as compared with a 4% reduction with placebo (P=0.0036 and P<0.0001 for the two comparisons), reported Mazen Noureddin, MD, of Houston Methodist Hospital.
As detailed here at the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases, a significantly higher percentage of patients in the investigational arms achieved a ≥30% MRI proton density fat fraction (MRI-PDFF) reduction at week 12 as well, with even greater reductions at the 6-mg dose level:
≥30% reduction on MRI-PDFF: 64% with the 6-mg dose vs 4% with placebo
≥50% reduction on MRI-PDFF: 41% vs 0%
Normalization of liver fat (<5%) on MRI-PDFF: 23% vs 0%
This higher dose-level also improved liver fibroinflammation, increased sex hormone binding globulin (SHBG, a predictor of histologic response), while being associated with low rates of gastrointestinal side effects and no cardiovascular adverse events (AEs).
No approved drug currently exists for the treatment of MASH (formerly nonalcoholic steatohepatitis [NASH]), though not for a lack of trying. Patients with the often symptom-less disease are at increased risk of progressive fibrosis and cirrhosis, and the condition represents the second leading cause of liver transplant.
https://www.medpagetoday.com/meetingcoverage/...ate_active
I look forward to the day when our advisors report on Leronlimab.
Ohm, is this a serious threat to Leronlimab's MASH potential? Excerpts and link are inserted below.
BOSTON -- Treatment with an investigational thyroid hormone receptor-beta (THR-β) agonist significantly reduced liver fat content in patients with metabolic dysfunction-associated steatohepatitis (MASH), a placebo-controlled phase IIa trial showed.
Significant reductions from baseline were seen as early as 6 weeks with the novel oral compound (TERN-501). By 12 weeks, mean relative reductions ranged from 27% to 45% with 3-mg and 6-mg doses of the THR-β agonist, as compared with a 4% reduction with placebo (P=0.0036 and P<0.0001 for the two comparisons), reported Mazen Noureddin, MD, of Houston Methodist Hospital.
As detailed here at the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases, a significantly higher percentage of patients in the investigational arms achieved a ≥30% MRI proton density fat fraction (MRI-PDFF) reduction at week 12 as well, with even greater reductions at the 6-mg dose level:
≥30% reduction on MRI-PDFF: 64% with the 6-mg dose vs 4% with placebo
≥50% reduction on MRI-PDFF: 41% vs 0%
Normalization of liver fat (<5%) on MRI-PDFF: 23% vs 0%
This higher dose-level also improved liver fibroinflammation, increased sex hormone binding globulin (SHBG, a predictor of histologic response), while being associated with low rates of gastrointestinal side effects and no cardiovascular adverse events (AEs).
No approved drug currently exists for the treatment of MASH (formerly nonalcoholic steatohepatitis [NASH]), though not for a lack of trying. Patients with the often symptom-less disease are at increased risk of progressive fibrosis and cirrhosis, and the condition represents the second leading cause of liver transplant.
https://www.medpagetoday.com/meetingcoverage/...ate_active
(1)
(0)
